Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1935]
News [3843]
Articles [101]
Editorials [5]
Conferences [164]
elearning [26]
MYSTIC: Developing biomarkers for metastatic NSCLC
Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...
MYSTIC: Developing biomarkers for metastatic NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
11 Apr 2019
Immune checkpoint inhibitor combination efficacious for patients with high...
Prof Sandip Patel - UC San Diego, San Diego, USA
Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine carcinoma ( Prof Sandip Patel - UC San Diego, San Diego, USA )
11 Apr 2019
Latest updates in melanoma research
Dr Alexander van Akkooi - The Netherlands Cancer Institute, Amsterdam...
Latest updates in melanoma research ( Dr Alexander van Akkooi - The Netherlands Cancer Institute, Amsterdam, Netherlands )
21 Mar 2019
Gynaecological cancer: Where are we now?
Dr Nelleke Ottevanger - Radboud University Medical Center, Nijmegen, Netherlands
Gynaecological cancer: Where are we now? ( Dr Nelleke Ottevanger - Radboud University Medical Center, Nijmegen, Netherlands )
21 Mar 2019
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non...
Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma ( Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )
19 Feb 2019
Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of...
Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA
Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer ( Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA )
19 Feb 2019
CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced...
Prof Nizar Tannir - MD Anderson Cancer Center, Houston, USA
CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma ( Prof Nizar Tannir - MD Anderson Cancer Center, Houston, USA )
16 Feb 2019
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell...
Prof Brian Rini - Cleveland Clinic, Cleveland, USA
KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )
14 Feb 2019
ASCO GU 2019 renal highlights
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
14 Feb 2019
Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma
Prof Brian Rini - Cleveland Clinic, Cleveland, USA
Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )
14 Feb 2019
Sacituzumab govitecan in patients with previously treated metastatic urothelial...
Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
14 Feb 2019
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer
Dr Arjun Balar - NYU Langone Health, New York City, USA
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer ( Dr Arjun Balar - NYU Langone Health, New York City, USA )
14 Feb 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation